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Summary
In a prototypical model of multistage tumorigenesis involving pancreatic islets in RIP1-Tag2 transgenic mice, activation
of insulin-like growth factor II (IGF-II) was previously shown to serve as a survival factor that inhibited apoptosis. Now
IGF-1R, the receptor tyrosine kinase for IGF-II, has been found to be variably upregulated, first uniformly in dysplastic and
angiogenic progenitors and then focally at the margins and in invasive regions of carcinomas. When the levels of IGF-1R
were forcibly elevated throughout islet tumorigenesis, progression was accelerated at all stages in the pathway, although
apoptosis was not differentially suppressed. Notably, encapsulated tumors were absent; instead, invasive carcinomas with
downregulated E-cadherin were prevalent, and the majority of mice had local lymph node metastasis.
Introduction focally upregulated as oncogene-expressing islet  cells be-
come hyperproliferative, populating hyperplastic and dysplastic
pancreatic islets; IGF-II levels increase and become more uni-Receptor tyrosine kinases are crucial intermediaries between
the extracellular milieu and intracellular signaling pathways that form in the subsequent stages of angiogenic (dysplastic) islets
and solid tumors (Christofori et al., 1994; Naik et al., 1994).together control cellular functions as diverse as the cell division
cycle, apoptosis, gene expression, cytoskeletal architecture, Knowledge of the role that IGF-II plays in this system came
from studies with mice in which IGF-II is genetically ablated.cell adhesion, and cell migration. As the mechanisms controlling
cell signaling are better understood, it has become clear that RIP1-Tag2, IGF-II null mice developed markedly smaller tumors
whose histopathology was suggestive of a more benign condi-dysregulation of these cellular functions at the level of ligand
binding, receptor signaling, or downstream intracellular signal- tion—the tumor cells were less prone toward nuclear atypia
and had more cytoplasm. Surprisingly, the proliferation indexing can have dramatic effects on cellular phenotype. Thus, it is
not surprising that activating mutations, gene amplification, or in progenitor islets and solid tumors was comparable to those in
wild-type RIP1-Tag2 mice, whereas the frequency of apoptosisepigenetic increases in gene expression that result in increased
receptor kinase activity are associated with a number of different was 5-fold higher (Christofori et al., 1994; Naik et al., 1994).
Thus, IGF-II was implicated as a survival factor that conveyedhuman cancers.
Studies of a transgenic mouse model of cancer (RIP1-Tag2) resistance to apoptosis in the course of oncogene-induced tu-
morigenesis, congruent with results from cell culture studies onin which the SV40 T antigen oncoproteins are expressed in the
 cells of the pancreatic islets under the control of the rat insulin the c-myc oncogene (Harrington et al., 1994).
The expression and activity of IGF-II is subject to multiplepromoter have proven instructive in delineating the cellular and
molecular mechanisms of multistep tumorigenesis (Folkman levels of regulation. IGF-II is expressed widely during embryonic
development in humans and rodents, but then transcription ofand Hanahan, 1996; Bergers et al., 1998; Hager and Hanahan,
1999). In particular, insulin-like growth factor-II (IGF-II) has been the Igf-II gene is variably downregulated and in some tissues
extinguished after birth (Stewart and Rotwein, 1996). In rodents,demonstrated to be a functional determinant of this tumorigene-
sis pathway, implicating signaling via a receptor tyrosine kinase, Igf-II gene expression is regulated in part by genomic imprinting
of the maternal allele (DeChiara et al., 1991; Ferguson-Smith etthe type I insulin-like growth factor receptor (IGF-1R). IGF-II is
S I G N I F I C A N C E
Tyrosine kinases have been widely implicated as causal agents for human cancers, motivating development of pharmacological
inhibitors designed to abrogate their functional contributions. While elevated expression of IGF-1R and its ligands has been reported
for many human tumors, the IGF signaling system has not been a prominent target for anticancer therapy. This report demonstrates
that IGF-1R can induce tumors arising de novo in the pancreas of mice into an invasive and metastatic growth program. Regulatory
determinants of invasion and metastasis remain elusive, and yet this is the hallmark of cancer that most often destines lethality. The
possibility that IGF-1 receptor signaling conveys invasive and metastatic capability in human tumors deserves broader investigation,
and prioritized development of pharmacological inhibitors may be warranted.
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al., 1991; Rappolee et al., 1992). Interestingly, loss of imprinting involvement of the IGF-1 receptor in the RIP1-Tag2 model. The
Igf-1R gene can be transcriptionally repressed by the p53 tumorand concomitant expression of both parental alleles is seen in
SV40 T antigen-induced  islet tumors (Christofori et al., 1995). suppressor protein in cultured cells (Werner et al., 1996), and
thus binding and inactivation of p53 by the SV40 large T onco-Bioavailability of the IGF-II protein is modulated in certain cir-
cumstances by a set of IGF binding proteins (IGF-BP), which protein (Ludlow, 1993) might be predicted to influence IGF-1R
expression. Further, studies with transformed fibroblasts havecan serve to prolong the half-life, sequester the protein within the
extracellular matrix, and influence its association with receptors. demonstrated a role for IGF-1R in SV40 T antigen-mediated
transformation (Sell et al., 1993), revealing a “transforming re-Release of free IGF-II can be accomplished by proteolytic degra-
dation of the IGF-BPs by proteases that include the kallikrein- gion” localized in the distinctive cytoplasmic signaling domain
(discussed above) not contained in the otherwise structurallylike serine proteases, cathepsins, and the matrix metalloprotein-
ases (MMPs), each of which are also extensively regulated on similar insulin receptor. Further, a physical association between
T antigen and IRS-1, a substrate of activated IGF-1R kinase, ismultiple levels (Grimberg and Cohen, 2000). IGF-II binds to two
receptors, the IGF-1R, a transmembrane tyrosine kinase, and crucial for transformation of fibroblasts in culture (Zhou-Li et
al., 1995). In light of these considerations, we first examinedIGF-2R, also known as the cation-dependent mannose-6 phos-
phate receptor; IGF-2R/M6P is thought to serve as a membrane in greater depth the endogenous expression of IGF-1R in the
discrete stages of tumorigenesis, revealing upregulation in pre-bound reservoir or depot for IGF-II, as it appears in general to
lack a capability for signal transduction (Braulke, 1999). malignant stages and, provocatively, in the invasive regions of
tumors. Then we upregulated expression of IGF-1R by produc-Studies in cell culture systems have revealed that IGF-1R
can induce a number of “transformed” cellular phenotypes, in- ing transgenic mice in which the Igf-1R gene was under tran-
scriptional control of the rat insulin promoter, and we examinedcluding hyperproliferation, protection from apoptosis, and tu-
morigenicity (Werner and LeRoith, 1996; Baserga et al., 1997); the effect of elevated levels IGF-1R in pancreatic  cells coex-
pressing the oncoprotein, SV40 large T antigen. The resultsmore recently, IGF-1R has been causally implicated in invasive
and metastatic growth by its ability to convey such capabilities demonstrate that increased IGF-1R expression can accelerate
progression through the stages of islet carcinogenesis, inducingon cultured epithelial cells (Dunn et al., 1998; Long et al., 1998b;
Xie et al., 1999; Brodt et al., 2001). IGF-1R can also be activated a more invasive and metastatic tumor phenotype.
by the other insulin-like growth factor, IGF-I, as well as by insulin;
these ligands have 10 times higher and 100 times lower affinities Results
for IGF-1R than IGF-II, respectively. Furthermore, it has recently
been demonstrated that all three ligands can bind to heterodim- Characterization of IGF-1R expression
in the RIP1-Tag2 pathwayers composed of IGF-1R and an alternatively spliced isoform
of the insulin receptor (IR-A), as well as to IR-A homodimers In a previous study, semiquantitative RT-PCR analysis of islets
representing distinct stages in the RIP-Tag2 progression path-(Frasca et al., 1999; Pandini et al., 1999; Vella et al., 2002). While
IGF-1R is structurally quite similar to the insulin receptor, it has a way suggested that levels of Igf-1R mRNA were increased
approximately 2-fold upon the initiation of hyperproliferation,distinctive region within its cytoplasmic kinase domain (Dupont
and LeRoith, 2001; Nakae et al., 2001). Mutational analysis of the persisting similarly in subsequent stages of the pathway (Naik
et al., 1994). Cognizant of the range of lesions present at a givencytoplasmic portion of IGF-1R has revealed that its functional
activities can be separated with mutations that individually abro- time and the potential for variability in expression at the cellular
level, we have now performed immunohistochemical analysisgate induction of proliferation, tumorigenicity, and resistance to
apoptosis (reviewed by Baserga et al., 1997), and now also of IGF-1R expression after categorizing hematoxylin- and eosin-
stained RIP1-Tag2 islet lesions as either normal islets, hyper-invasion and metastasis (Brodt et al., 2001). Thus, IGF ligand
signaling emanates from this receptor into multiple intracellular plastic/dysplastic islets, angiogenic islets, islet tumors or in-
sulinomas (IT) with well-defined margins and frequent fibrouseffector circuits, each of which can influence a cellular function
deemed important for tumor growth and progression. capsules, carcinomas with focal regions of invasion (IC-1), or
(rarely) broadly invasive carcinomas (IC-2). These categories,In regard to the insulin/IGF signaling system in the RIP-Tag
pathway, the current state of knowledge is as follows. (1) The detailed in Table 1, are based on gross morphological and de-
tailed histopathological characteristics, founded upon on exten-IGF-1 and IGF-2/M6P receptors are both expressed at low but
discernable levels in islet tumors and tumor-derived cell lines, sive experience with this model.
IGF-1R staining was performed on adjacent sections, andwith indications that the IGF-2/M6P depot/decoy receptor is
more abundant, as shown by ligand binding and RNA analyses the levels and patterns of expression were assessed. Initially,
RIP1-Tag2 islets, much as wild-type littermates (normal) (Figure(Naik et al., 1994). (2) Expression of the insulin receptor gene
is barely detectable in tumors (our unpublished observations). 1A), express a low, uniform level of IGF-1R, while both hyper-
plastic/dysplastic (Figure 1B) and angiogenic (Figure 1C) islets(3) Six of the known IGF-BP are expressed in normal islets
and tumors at similar levels (Grewal et al., 1999). (4) Insulin is have cells with a wide range of levels dispersed throughout the
lesion in a seemingly random pattern. The benign islet tumorsexpressed at high levels (Hanahan, 1985; Efrat et al., 1988),
whereas IGF-I is expressed at very low levels (Naik et al., 1994) (IT), with well-defined margins and frequent fibrous capsules,
evidence little or no detectable IGF-1R expression (Figure 1D).in islet tumors and tumor cell lines. And (5) as reviewed above,
the dormant IGF-II gene is activated and comes to be highly By contrast, islet carcinomas (IC-1 and IC-2) exhibit distinctive
IGF-1R expression at the tumor margins and invasive frontsexpressed, and its expression is functionally significant, sug-
gesting that IGF-II conveys an important, nonredundant signal (Figure 1E) and comparatively reduced levels in the interior (Fig-
ure 1F). Notably, the immunohistochemical analysis, althoughin the context of oncogene-induced islet tumorigenesis. Several
additional facts further motivated us to investigate the possible consistent with mRNA expression levels obtained by semiquan-
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Figure 1. IGF-1 receptor is variably upregulated during islet tumorigenesis in RIP1-Tag2 mice
Immunostaining of tissue sections was used to visualize expression of the endogenous mouse IGF-1 receptor. A shows a normal islet in a nontransgenic
littermate; inset shows the normal rabbit immunoglobulin-stained control. IGF-1R is upregulated in hyperplastic/dysplastic islets (B) and angiogenic islets
(C). There is little expression evident in islet tumors with clear margins lacking invasion (D). By contrast, expression of IGF-1R is elevated at the margins and
in invasive regions of islet carcinomas (E); interestingly, levels are reduced in the interior of carcinomas (F), much like for the benign islet tumors. The scale
bars represent 20 m.
titative RT-PCR, has revealed a striking variability between the Genetic upregulation of Igf-1R during
RIP1-Tag2 carcinogenesisinterior and periphery of invasive tumors and an apparent down-
regulation in the noninvasive islet tumors compared to the pro- We sought to test the hypothesis that induction of IGF-II and
increased expression of its receptor IGF-1R together play a rolegenitor lesions. The presence of high levels of IGF-1R in cells
at the margins and within frankly invasive regions suggests a in islet carcinogenesis by perturbing expression of the receptor
using transgenic mice. Previous studies had revealed that con-role for the IGF signaling in the acquisition and/or maintenance
of invasive growth program. stitutive upregulation of IGF-II in transgenic mice by expression
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stages of this pathway and its association with cell transforma-
tion, we sought to increase its levels throughout the stages
of islet carcinogenesis. Several lines of RIP7-Igf-1R transgenic
mice were generated, wherein a human Igf-1R cDNA was con-
trolled by a version of the rat insulin gene promoter that consists
of 9.5 kb of 5 flanking regulatory region and the 5 untranslated
region (see Experimental Procedures). The mature IGF-1 recep-
tor exists as a disulfide-linked heterotetramer composed of two
 and two  chains. Expression levels of the transgene-encoded
receptor were determined by immunoprecipitation of the intact
receptor and Western blot analysis of the 130–135 kDa  chain
of the IGF-1R. One line, RIP7-Igf-1RL1, expressed IGF-1R in the
pancreatic islets at a level comparable to that of the endogen-
ous Igf-1R gene in a human breast carcinoma line, MCF-7, that
has been used to study receptor signaling (Figure 2A); this
transgenic mouse line was selected for further characterization.
Immunohistochemical staining for IGF-1R expression in paraf-
fin-embedded pancreas sections from RIP7-Igf-1R single-trans-
genic mice demonstrated that IGF-1R was uniformly expressed
on the plasma membrane of cells throughout the islets (Figure
2B). Expression of IGF-1R in the islet  cells did not alter life
expectancy or glucose homeostasis as determined by fasting
glucose tolerance (data not shown). Consistent with the de-
scribed role of IGF-1R in controlling cell size (Stewart and Rot-
wein, 1996) through the phosphoinositide 3-kinase-dependent
serine/threonine protein kinase Akt (Tuttle et al., 2001), trans-
genic  cells exhibited an increased cytoplasmic to nuclear ratio
(Figure 2B), indicating that transgenic expression of human Igf-
1R gene resulted in sufficient levels of a functional receptor to
activate intracellular signaling of a previously ascribed pheno-
type. There was no gross or histological evidence for a trans-
formed phenotype in the RIP7-Igf-1R single-transgenic mice.
Next, the RIP7-Igf-1R transgenic mice were crossed with
RIP1-Tag2 mice, and islets in young double-transgenic mice
were examined by immunohistochemistry to confirm that IGF-
1R was upregulated in the context of oncogene expression.
Figure 2C shows that islet cells from 5-week-old double-trans-
genic RIP7-Igf-1R, RIP1-Tag2 mice have increased levels of
IGF-1R, and receptor expression was more uniform throughout
the islet than in the RIP1-Tag2 single-transgenic mice (Figure
1). Notably, even at 5 weeks of age, histological examinationFigure 2. Expression of human IGF-1 receptor in the islets of RIP7-Igf-1R trans-
genic mice (Figure 2C) revealed marked morphological differences in the
islets compared to the hyperplastic and early dysplastic stagesAmong several RIP7-Igf-1R transgenic lines produced, one (designated line
#1 or RIP7-Igf1RL1) was chosen for this study after hu-IGF-1R protein was (Figure 1B) in age-matched littermate RIP1-Tag2 mice. The
found to be expressed in islets at a similar level to that in a human breast boundary between some islets and adjacent exocrine pancre-
cancer-derived cell line, MCF-7 (A). Pancreatic islets were isolated, and
atic tissue was poorly defined, and cells could be seen extendingcell lysates were subjected to immunoprecipitation of intact IGF-1R followed
into the exocrine pancreas. We went on to assess the impactby Western blotting to detect the 130–135 kDa IGF-1R  chain. The apparent
molecular weight of hu-IGF-1R was consistently found to be slightly lower of constitutive upregulation of IGF-1R on islet carcinogenesis.
in this and several other transgenic mouse lines than in MCF-7 cells (data
not shown). Immunostaining with an antibody specific for IGF-1R revealed Increased Igf-1R expression acceleratesuniform expression in the islets of single-transgenic mice, with clear hypertro-
islet carcinogenesisphy of the islet  cells (B). When crossed to RIP1-Tag2, the islets in double-
transgenic mice also expressed IGF-1R at elevated levels, albeit without A cohort of RIP1-Tag2, RIP7-Igf-1R mice along with littermate
evident  cell hypertrophy, as illustrated for a dysplastic islet (C). The scale RIP1-Tag2 controls were aged and examined for life span and
bars are 20 m. for tumor phenotype at regular intervals. Survival time of the
RIP7-Igf-1R, RIP1-Tag2 mice was significantly decreased in
comparison to the RIP1-Tag2 mice. The double-transgenic mice
(n  12) lived on average 9.9 weeks in comparison to the 12.6of the Igf-II cDNA under control of the rat insulin promoter did
weeks typical for RIP1-Tag2 single-transgenic mice, in particularnot enhance tumorigenesis (Naik, 1996), suggesting that the
for littermate siblings of the cross that generated the compoundligand levels achieved by activation and progressive upregula-
mice. (The difference in life span is statistically significant, withtion of the endogenous Igf-II gene were not limiting. In light of
the complex patterns of expression of the Igf-1R gene in the p  0.0007 using the two-sample, two-tailed t test assuming
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Table 1. Staging criteria for H&E-stained pancreatic sections in mouse models of islet carcinogenesis
Lesional size (compared
Stage {Symbol} Nucleus/cytoplasm ratio to normal wt islets) Vascular morphology Margins with exocrine tissue
“Normal” Tag {N*} Similar to wt  cells Similar (0.2 mm Similar to wt islet capillaries Well-defined, similar to wt
diameter) islets
Hyperplastic/dysplastic Increased relative to wt Variably larger (0.2–0.5 Similar to wt islet capillaries Well-defined, similar to wt
islet {H/DI}  cells mm diameter) islets
Angiogenic islet {AI} Increased relative to wt Variably larger (1 mm Abnormal vessels appear- Well-defined similar to wt
 cells diameter) ing dilated and/or islets
torturous; blood islands
often evident
Islet tumor or insulinoma Increased relative to wt Much larger (1–10 mm Abnormal vessels appear- Well-defined with no
{Tum}  cells diameter) ing dilated and/or invasive regions; may or
torturous; blood islands may not have a fibrous
may be evident capsule and/or envel-
oped acinar islands or
single cells
Invasive carcinoma Increased relative to wt Much larger (1–10 mm Abnormal vessels appear- Focal regions of invasion
type 1 {IC-1}  cells diameter) ing dilated and/or with adjacent margins;
torturous; blood islands tumor cells intercalated
may be evident into exocrine tissue, and/
or present as fronds
projecting into normal tissue
Invasive carcinoma Increased relative to wt Variable, from similar to Variable, from normal in Widespread invasion with no
type 2 {IC-2}  cells normal islets up to small lesions to dilated evidence of margins:
large tumors, as and torturous in larger extensive intercalation of
above lesions tumor cells into exocrine
pancreas
The basis for these criteria came from exhaustive analysis here and elsewhere of RIP1-Tag2 transgenic mice.
N*, histologically normal, but expressing the Tag oncogene.
unequal variance.) All double-transgenic mice were dead by 11 analyses of RIP1-Tag2 mice, or if the continuous backcrossing
into the C57Bl/6 background (currently N40) has enabled it.weeks, while single-transgenic littermates lived up to 16 weeks.
Comparison of the frequency of islet lesions in the double-Remarkably, tumors were detectable in double-transgenic mice
transgenic mice revealed marked differences (Figure 4B). At 5at 7 weeks of age, significantly earlier than seen in the RIP1-
weeks, the earliest time examined, only 60% of double-trans-Tag2 single-transgenic mice. Tumor burden rapidly increased
genic islet lesions were identifiable as normal or hyperplastic/over 40-fold in the ensuing 2 week period (Table 2), whereas
dysplastic in comparison to almost 90% of islets in the single-the single-transgenic RIP1-Tag2 mice had not yet developed
transgenic mice. Moreover, at this time point, 30% of the lesionsmacroscopic tumors by this age.
in the double transgenic exhibit the tortuous, dilated vesselsWe next evaluated the temporal appearance and frequency
characteristic of an angiogenic islet, which is significantlyof tumor formation and of progenitor lesions in comparison to
greater than the 12% seen in the single-transgenic RIP1-Tag2the well-established parameters of the RIP1-Tag2 pathway. Islet
mice. Remarkably, the more benign islet tumors characterizedlesions from cohorts of RIP1-Tag2 controls and RIP7-Igf-1R,
by the presence of a well-demarcating tumor-exocrine bound-RIP1-Tag2 mice were analyzed for the frequency of distinct
ary were completely absent from the double-transgenic pancre-stages of RIP1-Tag2 tumorigenesis using the criteria detailed
ases at all time points. Instead, small invasive carcinomas werein Table 1. As described in earlier studies, the single RIP1-Tag2
detected in RIP7-Igf-1R, RIP1-Tag2 pancreases as early as 5mice exhibit a temporal pattern of lesional progression that
weeks of age (Figure 3B), and the frequency of the IC-2 lesionsbegins with normal, oncogene-positive islets, followed by the
at this young age was higher than at any time point in the RIP1-appearance of hyperplastic/dysplastic and angiogenic islet le-
Tag2 pathway (Figure 4B). Further, these invasive carcinomassions, and finally solid tumors begin forming at 10–12 weeks.
came to constitute nearly 40% of all lesions detected in theThe histological characteristics of the prototypical stages are
pancreas of late-stage (9- to 10-week-old) double-transgenicdescribed in Table 1 and illustrated in Figure 3A; the abundance
mice.of the various stages at ages 5–15 weeks is shown in Figure
4A. In the course of the extensive histological comparison per-
formed here (Table 2), we also detected uniformly invasive tu- IGF-1R enhances both proliferation and apoptosis
in premalignant stagesmors that lacked any vestige of the well-defined margins and
frequent encapsulation of the typical solid tumors seen in the We have previously implicated both increased cell proliferation
and varying rates of apoptosis in the progression of tumorigene-RIP1-Tag model. These small, uniformly invasive tumors (called
invasive carcinoma type 2, or IC-2; see Table 1 and Figure 3A) sis in the RIP1-Tag2 pathway, and in particular have suggested
that, as in many systems (Evan and Littlewood, 1998), the bal-were evident as early as 7 weeks of age, well before the more
benign tumor types were detectable. It is presently unclear ance between the rates of cell proliferation and cell death govern
tumor growth (Naik et al., 1996; Bergers et al., 1998; Hager andwhether this rare class of tumor was overlooked in the previous
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Figure 3. Morphology of the distinctive stages in islet carcinogenesis
Typical examples of the stages evident in the pathways to islet carcinogenesis are shown for standard RIP1-Tag2 mice (A) and for the predominant pathway
resulting from upregulation of IGF-1R in RIP1-Tag2, RIP7-Igf-1R double-transgenic mice (B). These morphologies are described in Table 1 and form the basis
for the quantitative comparison of the temporal appearance and statistical abundance of the stages seen during progression to invasive carcinoma of
the pancreatic islets. Note that the double-transgenic mice also develop IC-1 lesions, which are similar to that shown in A for RIP1-Tag2. Scale bars represent
20 m on all micrographs except the islet tumor and invasive carcinoma type 2 in A, where the scale is 40 m.
Hanahan, 1999). We assessed, therefore, both parameters in and/or IGF-II. In the double-transgenic mice, a significant in-
crease in the frequencies of cells in cycle are seen in the hyper-the pancreases of double-transgenic mice at defined points
during their lifetime. To assess proliferation frequencies, cells plastic/dysplastic and angiogenic lesions as compared with le-
sions from the single RIP1-Tag2 transgenic littermate. Byincorporating BrdU were quantitated in the histologically distinct
populations of islets and neoplastic lesions from nontransgenic contrast, the average proliferation rate seen in the tumors of
the double-transgenic mice was not enhanced in comparisoncontrols, from RIP7-Igf-1R, from RIP1-TAg2, and from double-
transgenic RIP7-Igf-1R, RIP1-TAg2 littermates (Figure 5A). Islets to the tumors in the RIP1-Tag2 single-transgenic mice.
To assess possible changes in the apoptotic rate as a conse-from the RIP7-Igf-1R single-transgenic mice possess a slightly
elevated level of BrdU incorporation (6.4%) when compared quence of increasing the levels of IGF-1R, the TUNEL assay
was performed on islet lesions from RIP1-Tag2 single- andto the nontransgenic littermate control (2.5%). The increase in
proliferation rate in the Igf-1R single-transgenic mice is consis- RIP7-Igf-1R double-transgenic littermates. As seen in Figure
5B, the frequency of TUNEL positive apoptotic cells is increasedtent with both the slight increase in islet size and the presence
of a functional receptor that may be activated either in a ligand- in normal, hyperplastic/dysplastic, and angiogenic lesions, but
remains unaltered in the more advanced lesions in the doubleindependent manner or by endogenous serum levels of IGF-I
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Table 2. Comparison of tumor burden and summary of lesional stages analyzed in wild-type versus Igf-1R-upregulated RIP1-Tag2 mice
Mice analyzed Lesions evaluated (total) Tumor burden (mm3)
Age RT2 DTg RT2 DTg RT2 DTg
5 weeks 4 4 380 272 0.5 0.5
7 weeks 4 3 488 220 0.5 1.21 	 0.45a
9 weeks 6 5 314 100 0.5 55.34 	 20.41b
12 weeks 6 ND 197 ND 37.7 	 20.26 ND
15 weeks 5 ND 76 ND 57.9 	 14.21 ND
Abbreviations: RT2, RIP1-Tag2; DTg, RIP7-Igf1R, RIP1-Tag2 double transgenic mice; ND, not available, as DTg mice are dead by 11 weeks.
a p  0.035
b p  0.0079
transgenics in comparison to the RIP1-Tag2 single-transgenic did not detect downregulation of E-cadherin in the islets of
RIP7-Igf1R single-transgenic mice (not shown), which indicatesmice. This result was unexpected, given the prediction that
IGF-1R would signal resistance to apoptosis in response to that additional factors are necessary to effect its suppression;
amongst the candidate cofactors in RIP1-Tag2 mice are theactivation of IGF-II. Thus, elevated IGF-1R differentially impacts
the growth phenotype, as reflected by the proliferation and induced IGF-II ligand, the expressed Tag oncoproteins, and the
proliferative condition the oncogene elicits.apoptosis rates: it initially enhances apoptosis and less so prolif-
eration in the earliest stages (compared to RIP1-Tag2 islets)
where IGF-II is off or focally low (Christofori et al., 1994); then, it Elevated IGF-1R increases pancreatic islet metastasis
comparatively upregulates proliferation in the angiogenic stage Suppression of E-cadherin has also been associated with in-
when IGF-II levels are elevated; and finally, it has no impact on creased but still relatively low-frequency metastasis in the RIP1-
either parameter in tumors. Tag2 model (Perl et al., 1998), motivating assessment of the
metastatic phenotype in the Igf-1R double-transgenic mice. In-
deed, the intrapancreatic lymph node (PLN) contained meta-IGF-1R downregulates E-cadherin
Cell-cell adhesion is an important component of the normal static nodules in 77% of the double-transgenic mice analyzed;
by comparison, 8.3% of single-transgenic RIP1-Tag2 mice hadarchitecture of the islets, and loss of those intercellular contacts
is postulated to be important for the development of malignancy. metastatic lesions (Table 3). More distant metastases were ob-
served only occasionally in RIP1-Tag2, RIP7-Igf1R mice; wePrior studies have demonstrated that loss of the gap-junction
protein E-cadherin is functionally involved in the transition from suspect the brief 10 week life span of the double-transgenic
mice limited the opportunity for distant metastases to developwell-differentiated adenoma to invasive carcinoma in the RIP1-
Tag2 pathway (Perl et al., 1998). Furthermore, downregulation macroscopically. The intrapancreatic lymph node is the initial
draining node for the pancreas (Cook, 1983; see also Mandriotaof E-cadherin is associated with the malignant phenotype in
many human cancers (Christofori and Semb, 1999; Cavallaro et al., 2001, and references therein). This local lymph node has
proved to be the predominant site for  cell metastasis in RIP-and Christofori, 2001). Given the prevalence of highly invasive
tumors in the double-transgenic mice, we sought to determine Tag2 mice, most notably in response to additional genetic per-
turbations. Thus, PLN metastasis was observed in the contextwhether E-cadherin expression was altered in the stages of islet
of dominant-negative suppression of E-cadherin (Perl et al.,carcinogenesis. Islets from single- and double-transgenic mice
1998), ablation of NCAM expression (Perl et al., 1999), or coex-were stained for both E-cadherin and large T antigen, with the
pression of the lymphangiogenic growth factor VEGF-C in theoncoprotein serving to visualize the neoplastic cells. Figures 6B
oncogene-expressing  cells (Mandriota et al., 2001). The pat-and 6D show a clear loss of E-cadherin expression in oncogene-
terns and relatively low frequencies of metastasis observed inexpressing cells in a relatively small double-transgenic islet le-
these studies led to the proposition that multiple factors governsion. A comparable lesion in the RIP1-Tag2 single-transgenic
the capability for islet metastasis (Cavallaro and Christofori,mice shows no loss of E-cadherin expression (Figures 6A and
2001). The comparatively high frequency of metastasis pro-6C). Visual inspection revealed downregulation of E-cadherin
duced by elevated levels of IGF-1R suggests that IGF-1R signal-to be prevalent but not absolute in the numerous islet lesions
ing affects more of the necessary conditions for the metastaticanalyzed in the double-transgenic mice. To substantiate that
growth program in addition to its clear association with down-conclusion, we sought to quantitatively assess the apparent
regulation of E-cadherin (Figure 6).downregulation of E-cadherin by performing image analysis of
the fluorescence intensity of E-cadherin immunostaining in islet
lesions compared to adjacent normal exocrine pancreas. Evalu- Discussion
ation of relative fluorescence intensity of E-cadherin in the differ-
ent stages of the generic tumorigenesis pathway confirmed Motivated by the correlation of IGF-II gene activation with the
onset of neoplastic proliferation in the RIP1-Tag2 tumorigenesisdownregulation in both invasive carcinoma stages but not in
progenitor islets or encapsulated islet tumors (Figure 6E). In pathway and by its functional association with resistance to
apoptosis, we sought to investigate the role played by one ofcontrast, E-cadherin expression in RIP1-Tag2, RIP7-Igf-1R mice
was decreased throughout tumorigenesis, in premalignant le- its receptors, IGF-1R. The insulin-like growth factor receptor
type 1 is a transmembrane tyrosine kinase with well-establishedsions as well as in invasive carcinomas (Figure 6E). Notably, we
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Figure 4. The temporal dynamics of multistage progression is accelerated
and biased by elevated IGF-1R
Using staging criteria summarized in Table 1, lesions were classified at various
time points in the life spans of RIP1-Tag2 (A) and RIP7-Igf-1R, RIP1-Tag2
double-transgenic (B) mice. Substantial numbers of lesions were evaluated
at the noted ages, as summarized in Table 2. Comparison of the islet lesions
in the cohorts of RIP1-Tag2 and RIP7-Igf-1R, RIP1-Tag2 mice at 5, 7, and 9
weeks of age demonstrated a statistically significant shift toward invasive
Figure 5. Elevated levels of IGF-1R selectively increase proliferation and apo-carcinomas (5 weeks, p  0.0304; 7 weeks, p  0.0518; 9 weeks, p  0.0051
ptosis in premalignat stages of islet carcinogenesisby the Wilcoxon score for variable grade).
The proliferation index (A) and the apoptotic index (B) in staged lesions
(Table 1) was determined and compared between RIP1-Tag2 single-trans-
genic and RIP1-Tag2, RIP7-Igf-1R double-transgenic mice. Differences be-
tween the two genotypes at a particular stage of carcinogenesis were
intracellular signaling capabilities, and a knowledge base of analyzed by the unpaired, two-tailed t test. For the proliferation index (A),
the significance values were: “normal” islets, p  0.6312; hyperplastic/dys-correlative and functional evidence implicates it in cancer phe-
plastic islets, p  0.0001; angiogenic islets, p  0.0001; and invasive carci-notypes. In generic RIP1-Tag2 single-transgenic mice, the en-
noma types 1 and 2 (combined), p  0.4647. The incidences of apoptosisdogenous IGF-1R protein was found to be upregulated from a
(B) were similarly compared at each stage, and the significance values
nearly undetectable level in normal pancreatic islets, coincident were: normal islets, p  0.1213, hyperplastic/dysplastic islets, p  0.0001;
with the transition from “normal” (oncogene-expressing) islets angiogenic islets, p  0.0005; and invasive carcinoma types 1 and 2 (com-
bined), p  0.1493. Notably, increased levels of IGF-1R did not reduceto hyperplastic/dysplastic islets, and concomitant with the het-
apoptosis, but rather increased both proliferation and apoptosis in the pre-erogeneous induction of its previously dormant ligand, IGF-II.
malignant stages while having no impact on the cancer stages. (The dou-
Receptor levels continued to be elevated in angiogenic islets, ble-transgenic mice do not develop encapsulated islet tumors (IT) lacking
but then shifted from the uniform expression pattern seen in invasive regions.)
these premalignant lesions to one where increased expression
was localized to cells at the periphery and invasive fronts of
established tumors, consistent with a role in promoting invasion.
but probably not all of the regulatory equation. Seeking to probeLittle or no expression was detectable in islet tumors with well-
the role of IGF-1R in this prototypical carcinogenesis pathway,defined margins and fibrous capsules, and expression was
transgenic mice were generated that constitutively expressedpatchy in the core of invasive carcinomas. We currently have
IGF-1R at elevated levels in the islet  cells of the pancreas.no clues into the dynamic regulation of endogenous IGF-1R
There was little effect on the islets of single-transgenic mice.levels in the stages of islet carcinogenesis. We suspect that
By contrast, in the context of tumorigenesis, IGF-1R clearlythe sporadic activation and heterogeneous expression of the
accelerated neoplastic progression, most dramatically by pro-dormant (and imprinted) IGF-II gene (Christofori et al., 1994,
1995) in  cells expressing the T antigen oncogene may be part moting the capability for invasion and metastasis.
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Figure 6. E-cadherin is downregulated early dur-
ing tumorigenesis in RIP-7-Igf-1R, RIP1-Tag mice
A and B show immunostaining (green) for
E-cadherin in hyperplastic/dysplastic islets of
5-week-old (A) single- and (B) double-transgenic
mice, revealing marked suppression of E-cadh-
erin in the latter. The regions devoid of E-cadherin
in B are tumor cells expressing the large T onco-
protein, as revealed by coimmunostaining for
Tag-expressing cells (labeled red); C and D show
the same islets visualized for both E-cadherin and
the oncogene. Downregulation of E-cadherin is
prevalent (but heterogeneous) in all subsequent
stages of the double-transgenic mice. Notably,
the invasive regions of islet carcinomas in both
single- and double-transgenic mice had re-
duced levels of E-cadherin (not shown), consis-
tent with the results of Perl et al. (1998). Scale
bars are 20 m. E: Islet lesions from five RIP1-Tag2
(n  121 total lesions) and four RIP1-Tag2, RIP7-
Igf-1R (n  76 total lesions) were categorized
according to the criteria outlined in Table 1, and
the ratio of mean fluorescence intensity of the
islet lesion/adjacent exocrine pancreas was de-
termined. Lesions were pooled from all mice of
the same genotype for statistical analysis. Immu-
nofluorescent staining revealed that the level of
E-cadherin is decreased in the double trans-
genic in comparison to the single transgenic in
the hyperplastic/dysplastic (p  0.002), angio-
genic (p 0.018), and invasive carcinoma type 1
(p 0.008) stages and equivalent in the invasive
carcinoma type 2 (p  0.325) by the two-tailed
t test assuming unequal variances.
In designing this study, we predicted that elevating the levels signaling. Evaluation of proliferation and apoptosis frequencies
in the different lesional stages demonstrated that both prolifera-of IGF-1R throughout tumorigenesis would cause a generalized
decrease in apoptosis at all stages, much as we observed when tion and apoptosis rates were significantly increased in the pre-
malignant stages, contrary to expectations. The discrepancythe antiapoptotic factor Bcl-XL was similarly upregulated (Naik
et al., 1996). The basis for this prediction came not only from between the protection from apoptosis afforded by IGF-II upreg-
ulation in the standard RIP1-Tag2 pathway and the increasedthe analysis of the phenotype in RIP1-Tag2, IGF-II null mice,
but also from analysis of mice that had IGF-II constitutively apoptosis in progenitor lesions in the RIP1-Tag2, RIP7-Igf-1R
transgenic mice may have a basis in the dynamics of signalupregulated. A RIP7-IGF-II transgenic line was produced and
shown to express high levels of IGF-II in normal islet  cells transduction. Ligand binding to IGF-1R has been shown to in-
duce at least three intracellular signaling pathways: MAP kinase,without consequence; when crossbred to RIP1-Tag2, the dou-
ble-transgenic mice had unchanged proliferative and apoptotic phospholipase C
, and phosphoinositol 3-kinase. Mutational
analyses of key residues in the cytoplasmic domain of the IGF-profiles during tumorigenesis (Naik, 1996). From this, we con-
cluded that the levels of IGF-II resulting from upregulation of 1R  chain have demonstrated that it is possible to functionally
separate the survival, proliferation, transformation, and invasive/the endogenous IGF-II gene were sufficient to manifest its con-
tributions to tumorigenesis, and therefore we postulated that metastatic responses (Baserga et al., 1997; Brodt et al., 2001).
Moreover, analysis of the MAP kinase pathway in other cellthe low levels of its receptor might be limiting. Indeed, the results
of elevating this IGF receptor suggest that is the case, but in culture models has shown that decisions between cell survival
and apoptosis as well as between proliferation and cell cycleaddition they have revealed an intriguing complexity to IGF-1R
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Table 3. Frequency of metastasis to the local pancreatic lymph nodes
Number of Age Mice with PLN Frequency of
Transgenic genotype mice analyzed (weeks) metastasis metastasis
RIP1-Tag2 (colony) 12 13–14 1 8.3%
RIP1-Tag2 (littermates) 12 11–16 1 8.3%
RIP1-Tag2, RIP7-Igf-1RL1 9 8–10 7 77%
In this analysis, RIP1-Tag2 and RIP1-Tag2, RIP7-Igf-1R pancreases were collected, fixed, and serially sectioned, and tissue sections every 100 m were
evaluated to reveal the pancreatic lymph nodes (PLN), which are the inital collecting point for the pancreatic lymphatic vasculature. The frequency of
metastasis reported in generic RIP1-Tag mice has varied historically (Grant et al., 1991, Perl et al., 1998), perhaps as a function of genetic background,
backcross generation, and age. To compare RIP1-Tag2 mice having the closest possible genetic background to the double transgenic mice at a similar
stage of disease progression, a cohort of single transgenic RIP1-Tag2 littermates were sacrificed somewhat later than when their double transgenic siblings
were at endstage and both were analyzed. Separately, endstage RIP1-Tag mice from the standard breeding colony were evaluated. Histological analyses
by H&E, confirmed by insulin immunostaining, established the presence of metastatic nodules inside the lymph nodes. The difference in metastatic frequency
is statistically significant compared to both RIP1-Tag2 cohorts (p  0.0022 for the double transgenic mice versus RIP1-Tag littermates, and p  0.0022 versus
RIP1-Tag mice from the colony, as determined using the Fisher’s Exact test).
arrest can be effected through alternative signaling thresholds downregulated (Perl et al., 1998). Our interpretation is that sig-
nals from IGF-1R and from the Tag oncogene collaborate, likelydetermined by both the strength and duration of the activating
signal (Woods et al., 1997; Cook et al., 1999). Based on these with additional agents (perhaps IGF-II), to effect E-cadherin
downregulation, a possibility that deserves future investigation.considerations, we envision that the modest upregulation of
IGF-1R in premalignant lesions of RIP1-Tag2 single-transgenic It is pertinent to consider other candidate effectors of inva-
sion and metastasis elicited by IGF-1R signaling, as there ismice establishes the receptor at a level that primarily signals
antiapoptosis. Then, when the receptor level is further elevated reason to suspect that suppression of E-cadherin is necessary
but not sufficient. One rationale involves the comparatively lowvia the transgene, a threshold is crossed such that the predomi-
nant signaling output is biased to the proliferative and invasive/ frequency of metastasis seen when E-cadherin was suppressed
(Perl et al., 1998) relative to when IGF-1R levels were elevatedmetastatic effector circuits instead of antiapoptosis. We suspect
that the invasive effector signal is also activated (but perhaps (this study), suggesting that IGF-1R signaling regulates other
effectors of invasion. A second is that invasive carcinomas ariseto a lesser extent) by the focally elevated IGF-1R seen in the
invasive regions of carcinomas of RIP1-Tag2 single-transgenic much earlier and at higher frequency in the case of IGF-1R
upregulation than in that involving forcible E-cadherin downreg-mice. Additional considerations involve the heterogeneous ex-
pression of IGF-II, the potential of IGF binding proteins to modu- ulation. Several previous studies have identified candidate ef-
fectors of invasive and metastatic capabilities regulated by IGF-late its bioavailability, and the possible involvement of the other
IGF-1R ligands, IGF-I, and insulin. Moreover, the insulin receptor 1R in cultured cells: Dunn et al. (2001) found that urokinase
was upregulated by IGF-1R in the MDA-MB-213 human breastis now known to have an alternative isoform with higher IGF
affinity (Frasca et al., 1999; Vella et al., 2002) and the potential cancer line, and Long et al. (1998a) reported IGF-1R regulation
of MMP-2 in a variant Lewis lung carcinoma line, whereas Mirato make functional heterodimers with IGF-1R (Pandini et al.,
1999). It will be of interest to assess the possible contributions et al. (1999) found that MMP-9 was induced by IGF-I in MCF-7
human breast cancer cells. Extracellular proteases have longof these members of the IGF axis to islet carcinogenesis.
been implicated in invasion and metastasis, and as such these
are attractive candidates that bear investigation in the RIP1-E-cadherin and other effectors of IGF-1R invasive
and metastatic signaling Tag2, RIP7-Igf-1R tumorigenesis pathway. A counterpoint is
that neither urokinase, MMP-2, nor MMP-9 appear to be individ-IGF-1R signaling has long been associated with cellular transfor-
mation and more recently with invasion and metastasis (Dunn ually important for induction of the invasive phenotype in islet
carcinomas arising in the wild-type RIP1-Tag2 model. The evi-et al., 1998; Long et al., 1998b; Xie et al., 1999; Brodt et al.,
2001). So too has suppression of E-cadherin, a cell adhesion dence comes from gene knockout mice lacking each of these
proteinases and from pharmacological inhibition studies withmolecule causally associated with invasion in this model and
in a variety of human cancers (Christofori and Semb, 1999; MMP inhibitors that target MMP-2 and MMP-9. When gene
knockouts for urokinase (uPA), MMP-2, or MMP-9 were cross-Cavallaro and Christofori, 2001). Two previous reports have
suggested a possible connection between E-cadherin and IGF- bred into the RIP-Tag2, and the protease null mice were ana-
lyzed, the surprising result was that mice lacking any one of1R signaling: Andre et al. (1999) and Playford et al. (2000) each
reported that IGF-I ligand increased tyrosine phosphorylation these three proteases still developed highly invasive islet carci-
nomas (Bergers et al., 2000); MMP-2 and MMP-9 were, how-of -catenin in colon carcinoma cell lines, resulting in dissocia-
tion of E-cadherin from the plasma membrane, thereby sup- ever, demonstrably important for tumor growth. Furthermore,
treatment of RIP1-Tag2 mice with MMP inhibitors also impairedpressing its cell adhesion function. Here, by elevating IGF-1R
levels in the RIP-Tag2 pathway, we have shown that E-cadherin tumor growth but did not affect progression to invasive carcino-
mas (Bergers et al., 1999, 2000). Finally, MMP-9 was not ex-is downregulated early and far more prevalently that in the un-
perturbed pathway, where IGF-1R levels are more variable. No- pressed by the islet tumor cells coexpressing the Tag oncogene,
IGF-II, and IGF-1R; rather, it is expressed in perivascular in-tably, the data presented above show that IGF-1R is expressed
at the highest levels in single RIP1-Tag2 tumors at the bound- flammatory cells (Bergers et al., 2000, and unpublished observa-
tions of the Hanahan laboratory). While these data argue againstaries and in invasive regions, where E-cadherin is known to be
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their involvement in local invasion in the pancreas, we cannot
exclude that one or another of these proteinases will prove to be
induced in metastatic islet tumor cells and functionally involved
therein; the possibility deserves future investigation. Similarly,
the suggestions that IGF-1R-induced invasiveness is dependent
on upregulation of integrins (Mira et al., 1999) or phosphorylation
of -catenin and IRS-1 (Playford et al., 2000) should be consid-
ered. While these candidates may or may not prove to be the
implicit cofactors or the functional effectors of E-cadherin sup-
pression that are necessary for signaling of invasion and metas-
tasis by IGF-1R, we expect the critical genes will be identified
as new candidates presented from other systems or by compar-
ative analysis in the various RIP-Tag models, who are then
confirmed via genetic manipulation of their functionality during
islet carcinogenesis.
IGF-1R directs tumorigenesis into an invasive
growth program
In the course of analyzing the effects of elevating the levels of
the IGF-1R throughout the well-established RIP1-Tag2 tumori-
genesis pathway, the complete spectrum of lesions was thor-
oughly examined at three different time points (5, 7, and 9 weeks
of age) in both the RIP1-Tag2 single- and RIP1-Tag2, RIP7-Igf-
1R double-transgenic mice. The analysis of the single-trans-
genic mice confirmed the multistep paradigm proposed in earlier
Figure 7. A modified pathway of multistage tumorigenesis of the pancreaticstudies in the RIP1-Tag2 model. Although expression of the
islets in RIP1-Tag2 miceoncoprotein is known to initiate in the embryonic pancreas (Al-
Extensive analysis of the temporal appearance and histological characteris-pert et al., 1988), the islets were found to be histologically “nor-
tics of lesional stages that appear in the pancreas of RIP1-Tag2 mice sug-mal” until 3–4 weeks after birth, when a subset activated diffuse
gests a branched pathway to invasive carcinoma, as shown in A; the stages
 cell hyperproliferation and concomitant apoptosis, developing are described in Table 1 and exemplified in Figure 3A. The prevailing evi-
the histological characteristics of hyperplasia and dysplasia. Of dence from this study and those of Christofori and colleagues implicates a
major pathway wherein angiogenic dysplasias (“angiogenic islets”) in RIP1-these lesions, a subset switched on angiogenesis, as evidenced
Tag2 mice progress predominantly to islet tumors with well-defined marginsby the dilated, tortuous vasculature and microhemorrhaging
that lack invasion. Invasive regions subsequently appear, focally projectingcharacteristic of the angiogenic islet stage. At 5 weeks, all of out of such well-defined islet tumors, producing the invasive carcinoma
these lesions are evident (Figures 3 and 4). Islet tumors with type 1 (IC-1), which is relatively frequent (8%–10% of islets at risk at 15 weeks).
An exhaustive histopathological analysis (Table 2) of RIP1-Tag single-trans-well-defined margins and often capsules (IT) begin appearing
genic mice has revealed a less-frequent carcinoma that lacks evidenceat about 10 weeks, which then progress into tumors with focal
for a margin or capsule (invasive carcinoma type 2, IC-2). Both carcinomainvasive regions (invasive carcinoma type 1, or IC-1), represent-
types may produce the infrequent metastases observed. Elevated expres-
ing at endstage approximately 5% of the 400 pancreatic islets sion of IGF-1R biases the branched pathway in favor of the otherwise minor
“at risk.” In addition, our analysis of 7- and 9-week-old RIP1- IC-2 branch (B), in part by suppressing expression of E-cadherin, producing
a high incidence of broadly invasive carcinomas (40% of the focal isletTag2 mice has revealed the presence of rare, highly invasive
lesions at 9 weeks) and frequent local metastasis. These results, consideredlesions that appear to have developed in the absence of progeni-
in the context of independent studies in other experimental systems, suggesttor tumors (IT) having well-defined margins. We now propose that elevated levels of IGF-1R may be a causal factor in neoplastic progres-
this class of tumor arises via a heretofore unappreciated minor sion to highly invasive and metastatic phenotypes in settings of natural
carcinogenesis.pathway leading directly from angiogenic islets to widely inva-
sive carcinomas that lack both an identifiable capsule and a
clear margin with adjacent exocrine pancreas (IC-2). In Figure
7A, we have diagrammed this modification of RIP1-Tag2 path-
nomas, with a spectrum of sizes ranging from microscopic (simi-way, in which a branch point at the hyperplastic/dysplastic or
lar to islets) to macroscopic. By contrast, 9-week-old RIP1-Tagangiogenic islet stage shunts a subset of progenitor lesions
single-transgenic mice lacked macroscopic tumors of any classaway from the path to encapsulated islet tumors, directing them
(IT, IC-1, or IC-2) and had at most 1–2 microscopic IC-2 lesions.instead to form highly invasive carcinomas.
These comparisons make an important point, namely that theThe existence of a branch in the tumorigenesis pathway
highly invasive carcinomas induced by IGF-1R do not reflect athat leads directly to invasive carcinoma is corroborated by our
novel phenotype peculiar to the RIP1-Tag2, RIP7-Igf-1R miceanalysis of tumorigenesis in the double-transgenic RIP1-Tag2,
overexpressing IGF-1R. Rather, the IGF-1R transgene biasesRIP7-Igf-1R mice. Elevated levels of IGF-1R accelerated the
carcinogenesis in favor of a newly appreciated branch of thetemporal appearance and abundance of hyperplastic/dysplastic
pathway that is also evident in single-transgenic RIP1-Tag2and angiogenic islet lesions and of highly invasive carcinomas
mice. Our revised view of the islet carcinogenesis pathway that(IC-2). There was, remarkably, a complete absence of benign
unfolds in RIP1-Tag mice diagrammed in Figure 7, both forislet tumors (IT). At 9 weeks, 40% of the islets in the double-
transgenic mice had already progressed to highly invasive carci- the RIP1-Tag2 single-transgenic case (Figure 7A) and for the
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tory sequences included the proximal promoter-enhancer region and mostillustrative perturbation whereby the levels of IGF-1R were forc-
of the 5 untranslated region of the transcribed portion of the gene with itsibly elevated (Figure 7B). Thus, while we have historically pre-
associated small intron. Plasmid DNA was isolated using standard methodssented islet carcinogenesis as a simple linear pathway, we now
and purified by cesium density gradient for microinjection. The RIP7-Igf-
consider it as branched, wherein the invasive growth program 1R mice were produced by DNA microinjection into zygotes of a C3B6F2
can be induced at early or late stages, with a likely determinant genotype using standard techniques. Mice were initially identified by South-
being variable dynamics of upregulating IGF-1R. Interestingly, ern blot. Genetic screening to identify the transgene was performed by
we have previously shown that genesis of intestinal carcinoids, PCR using the following primers: 5-GATGTTGTAGGTGTCTGCGGC and 5-
GACGGCACCATCGACATTGAGG. The identified transgenic founder micearising from a related neuroendocrine cell type in the gut in a
(including the line #1 described here) were backcrossed to C57Bl/6 forvariant genetic background of RIP1-Tag2, also evidences early
2–5 generations and then crossed to RIP1-Tag2 mice (effectively inbred ininvasiveness in a pathway that similarly lacks an encapsulated
C57Bl/6, N40) to generate double-transgenic mice. Unless noted, lit-
tumor stage (Grant et al., 1991). termate RIP1-Tag2 single-transgenic mice were used in comparisons to
the double-transgenic mice. In some cases, late-stage RIP1-Tag2 single-
A perspective on IGF signaling for the capabilities transgenic mice from the core colony (N40 in C57Bl/6) were separately
analyzed. The RIP7-Igf-1RL1 lineage was maintained by backcrossing trans-of carcinomas
genic males and females with C57Bl/6 females and males (Jackson Labora-The results of this investigation support a proposition that ele-
tory), whereas only RIP1-Tag2 males were used for breeding.vated expression of IGF-1R in the presence of both a ligand,
IGF-II, and an oncoprotein, in this case the SV40 large T antigen
Tissue preparation
that abrogates the pRb and p53 tumor suppressors, can en- Pancreases were removed and either fixed overnight in 4% paraformalde-
hance malignant progression, in particular evoking the capability hyde in 1 PBS or immediately placed in OCT (Tissue-Tek) and frozen in a
for invasion and metastasis, thought to be crucial for most CO2/ethanol bath. Fixed tissue was dehydrated through 30%, 50%, 70%,
80%, 95%, and 100% ethanol and 100% xylene before embedding in paraf-cancers (Hanahan and Weinberg, 2000). Elucidation of the
fin (Paraplast). Fixed and frozen tissues were cut into 5 m and 10 mmechanisms regulating the invasive and metastatic growth pro-
sections, respectively.gram remains a major agenda for cancer biology. One well-
characterized invasive growth regulator is another receptor tyro-
Histology and immunohistochemistry
sine kinase, c-met, which is capable of both ligand-dependent Frozen sections were air dried prior to acetone fixation, while paraffin-
and ligand-independent signaling (Furge et al., 2000; Comoglio embedded sections were rehydrated through 100% xylene, 100%, 95%,
et al., 1999; Wang et al., 2001). Notably, c-met is able in some 70%, and 50% ethanol before immersion in 1 PBS. For hematoxylin and
eosin staining, sections were stained with hematoxylin Gill #3 and eosin Ycircumstances to downregulate E-cadherin (Hiscox and Jiang,
(Sigma) according to standard protocols. For immunohistochemistry, frozen1999; Noe et al., 1999), perhaps the best-characterized effector
sections were routinely blocked for nonspecific biotin binding with a blockingof the invasive phenotype. Herein we show that a second recep-
kit (Vector Laboratories) diluted in 1% bovine serum albumin (Fraction V,tor, IGF-1R, can elicit invasive and metastatic capabilities in the
Sigma) in 1 PBS. All tissue sections were blocked in 1% bovine serum
context of oncogenesis and that these phenotypes are also albumin in 1 PBS prior to addition of the primary antibody. The following
associated with downregulation of E-cadherin. Thus, IGF-1R immunoglobins were used as negative controls for the species-matched
may well serve as another key regulator of the invasive growth primary antibody: rat IgG (ChromoPure Rat IgG whole-molecule Jackson
ImmunoResearch), mouse IgG (MOPC 21, clarified ascites, Sigma), andprogram. It is pertinent to recall, in this context, that a consider-
rabbit IgG (Vector Laboratories). The following antibodies were used forable body of research has documented elevated expression in
specific staining: monoclonal rat anti-mouse E-cadherin (ECCD-2; 1:800;human tumors of IGF-1R and its primary ligands, IGF-I and IGF-
Zymed Laboratories), rabbit polyclonal anti-IGF-1R (SC-712; 1:250; SantaII (e.g., Macaulay, 1992; Quinn et al., 1996; Werner and LeRoith,
Cruz Laboratories), and rabbit polyclonal anti-large T antigen (1:250; Hana-
1996; Grothey et al., 1999; Xie et al., 1999; Scharf et al., 2001). han laboratory preparation). The following secondary antibodies were used
This correlative data supports the conclusions of the functional at a 1:200 dilution: biotinylated goat anti-rabbit IgG (Vector), biotinylated
studies performed here in a mouse model of carcinogenesis goat anti-rat IgG (Vector), and Cy3-conjugated AffiniPure F(ab2) goat anti-
mouse IgG  IgM (Jackson ImmunoResearch). Biotinylated antibodies wereand by others in a variety of cell-based assay systems. Collec-
developed with either FITC-conjugated streptavidin (1:200; BD Pharmingen)tively, the evidence encourages the prediction that IGF-1R will
or Vectastain Elite ABC kit (Vector Laboratories) with Fast DAB (33Diamino-prove to make profound functional contributions to the develop-
benzidine tetrahydrachloride; Sigma). Fluorescently labeled tissues werement of human cancer, conveying in some organs (and perhaps
mounted in Vectashield Mounting Medium with DAPI (Vector Laboratories).
in early stages of tumorigenesis) resistance toward apoptosis,
OCT-embedded samples were counterstained with 1% methyl green and
and in other organs (or later stages of progression) capability dehydrated in isobutanol and xylene before mounting in Cytoseal #60
for invasion and metastasis. As such, it is reasonable to suggest (Fisher). Paraffin-embedded samples were counterstained with hematoxylin
that broader efforts are warranted to evaluate the expression followed with a brief incubation in dilute ammonium hydroxide solution before
sequential dehydration in 70%, 95%, and 100% ethanol and 100% xylene,of IGF-1R and its ligands in human cancers and to develop
and then mounting as above.pharmacological inhibitors of IGF-1R signaling.
Bromodeoxyuridine labelingExperimental procedures
Mice were injected intraperitoneally with 5-bromo-2-deoxyuridine (Sigma)
to give a final dose of 100 g BrdU/g body weight and euthanized 2 hrTransgenic mice
later. Tissues were collected and prepared as described above for paraffinThe RIP7-IGF-1R transgene utilized a full-length cDNA clone of the human
embedding. The 5-Bromo-2-Deoxy-Uridine Labeling and Detection Kit IIinsulin-like growth factor type 1 (Igf-1R) gene (Ullrich et al., 1986) that had
(Roche) was used with the following modifications. After deparaffinizationbeen shown to be biologically active when transfected in an expression
and rehydration, antigen retrieval (Citra Solution, Biogenex) was performedvector into cultured mammalian cells (Yamasaki et al., 1991). The Igf-1R
according to the manufacturer’s protocol. Anti-BrdU was detected withcDNA was inserted as a 4.4. kb fragment into the RIP7 vector (Naik et al.,
biotinylated goat anti-mouse IgG (1:200; Vector Laboratories) and then pro-1996), which consists of 10 kb of the 5 flanking region of the rat insulin
II gene carried in a Bluescript-derived plasmid vector; the insulin gene regula- cessed for biotinylated antibodies as described above.
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apoptosis are cellular parameters of neoplastic progression in transgenicTdT-mediated dUTP-digoxigenin nick-end labeling was done on paraformal-
tumor models of tumorigenesis. Int. J. Dev. Biol. 42, 995–1002.dehyde-fixed, paraffin-embedded tissues. Sections were prepared as de-
scribed above and preincubated with Proteinase K solution (undiluted, Dako) Bergers, G., Javaharian, K., Folkman, J., and Hanahan, D. (1999). Effects
for 3 min followed by an incubation with 0.15 M NaCl, 0.5% bovine serum of angiogenesis inhibitors on multistage carcinogenesis in mice. Science
albumin in TdT buffer (Invitrogen). Sections were incubated with terminal 284, 808–812.
deoxynucleotidyl transferase (200 U/ml; Invitrogen) and alkali-stable digoxi-
Bergers, G., Brekken, R., McMahon, J., Vu, T., Itoh, T., Tamaki, K., Tanzawa,genin-conjugated dUTP (2 M; Boehringer-Mannheim) diluted in TdT buffer.
K., Thorpe, P., Itohara, S., Werb, Z., and Hanahan, D. (2000). Matrix metallo-Finally, sections were incubated with horseradish peroxidase-conjugated
proteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell
Fab fragments of sheep anti-digoxigenin-POD (5 U/ml; Roche). The horse- Biol. 2, 737–744.
radish peroxidase reaction, counterstaining, and mounting were carried out
Braulke, T. (1999). Type-2 IGF receptor: a multi-ligand binding protein. Horm.as above.
Metab. Res. 31, 242–246.
Immunoprecipitation and Western blot Brodt, P., Fallavollita, L., Khatib, A.-M., Samini, A.A., and Zhang, D. (2001).
Islets from nontransgenic and RIP7-Igf-1R mice were isolated by hand pick- Cooperative regulation of the invasive and metastatic phenotypes by differ-
ing individual islets from collagenase Type XI (Sigma)-digested, Ficoll gradi- ent domains of the type I insulin-like growth factor receptor  subunit. J.
ent-sedimented pancreases. Islets and MCF-7 cells were lysed in 50 mM Biol. Chem. 276, 33608–33615.
Tris (pH 7.5), 150 mM NaCl, 1% NP-40, 0.1% SDS, 0.5% Na deoxycholate,
Cavallaro, U., and Christofori, G. (2001). Cell adhesion in tumor invasion and0.02% Na azide, and complete EDTA-free protease inhibitor cocktail (Roche
metastasis: loss of the glue is not enough. Biochim. Biophys. Acta 1552,
Applied Science). Protein concentration was determined by protein assay
39–45.
(BioRad), and equal amounts were precleared with protein G agarose
Christofori, G., and Semb, H. (1999). The role of the cell-adhesion molecule(GIBCO-BRL/Invitrogen) before incubating with the mouse monoclonal
E-cadherin as a tumor-suppressor gene. Trends Biochem. Sci. 24, 73–76.MOPC 21 (myeloma IgG; Sigma) or IR3 (specific for human, mouse, and
rat IGF-1R; Oncogene Science) and protein G agarose. Immunoprecipitated Christofori, G., Naik, P., and Hanahan, D. (1994). A second signal supplied
protein was boiled in loading buffer with -2 mercaptoethanol and run on by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature
a 8% SDS-polyacrylamide gel. Proteins were blotted on Immobilon-P mem- 369, 414–418.
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